1. Introduction {#sec1-ijms-19-02237}
===============

Cancer is the second most common cause of death in the US and worldwide and is exceeded only by heart disease. About 1.7 million new cancer cases are currently diagnosed in the US alone \[[@B1-ijms-19-02237]\]. Reductions in smoking as well as improvements in early detection and treatment has shown a decline in a variety of cancers including lung and breast cancer. However, there is still poor survival outcomes in metastatic cancers including lung, breast, and ovarian cancers. The new and promising target Protease-activated receptor-1 (PAR1) is associated with solid tumor progression including primary growth, invasion, metastasis, and angiogenesis \[[@B2-ijms-19-02237],[@B3-ijms-19-02237],[@B4-ijms-19-02237],[@B5-ijms-19-02237],[@B6-ijms-19-02237],[@B7-ijms-19-02237]\]. This review will focus on its functional role and evaluate PAR1 as a potential therapeutic target in breast, lung, and ovarian cancer. We will discuss the role of PAR1-biased signaling of the proteolytic action of canonical (thrombin) and non-canonical (collagenase matrix metalloprotease 1 (MMP-1)) \[[@B2-ijms-19-02237],[@B8-ijms-19-02237]\]. Our laboratories have developed an approach to study receptor-mediated G protein activation using palmitoylated peptides, which are also known as pepducin technology that act as allosteric modulators of GPCR-dependent G-protein signaling \[[@B9-ijms-19-02237],[@B10-ijms-19-02237],[@B11-ijms-19-02237]\]. PAR1 derived pepducin PZ-128 is in a Phase II clinical trial for thrombotic indication \[[@B11-ijms-19-02237],[@B12-ijms-19-02237],[@B13-ijms-19-02237]\]. The effects of PZ-128 in multiple cancer preclinical studies will be discussed.

2. PAR1 Structure, Function, and Downstream Interactors {#sec2-ijms-19-02237}
=======================================================

2.1. PAR1 Structure and Protease Activation {#sec2dot1-ijms-19-02237}
-------------------------------------------

PAR1 is a family member of the four PARs that also include PAR2--4, which act as exquisite sensors to a select group of proteases \[[@B14-ijms-19-02237]\]. PAR1 is classically activated through thrombin \[[@B15-ijms-19-02237]\] by cleaving its exodomain at the R~41~--S~42~ peptide bond ([Figure 1](#ijms-19-02237-f001){ref-type="fig"}) \[[@B15-ijms-19-02237],[@B16-ijms-19-02237],[@B17-ijms-19-02237]\]. Matrix metalloproteases (MMPs) are well known as important mediators of both atherothrombotic disease \[[@B18-ijms-19-02237],[@B19-ijms-19-02237]\] and cancer \[[@B2-ijms-19-02237],[@B20-ijms-19-02237],[@B21-ijms-19-02237],[@B22-ijms-19-02237],[@B23-ijms-19-02237]\]. This is especially relevant for the metastatic processes since physiologic levels of *MMPs* are low, but expression is elevated in most invasive cancers \[[@B2-ijms-19-02237],[@B18-ijms-19-02237],[@B24-ijms-19-02237]\].

PAR1 expression is increased in a number of cancers including breast, colon, and lung cancer. A study using a xenograft model of breast carcinoma cells originally demonstrated a critical role for MMP-1 derived from tumor-infiltrating fibroblasts in the cleavage of PAR-1, which appears to drive cancer cell migration and invasive behavior of the tumor \[[@B2-ijms-19-02237]\]. This finding led to a change in the central dogma that PAR1 can be cleaved at a divergent site from thrombin and activated by specific proteolysis by noncanonical MMP-1 at LD~49~\^P~50~RSFL ([Figure 1](#ijms-19-02237-f001){ref-type="fig"}). PAR1 is also activated by murine MMP-1, namely MMP-1a \[[@B21-ijms-19-02237],[@B22-ijms-19-02237],[@B23-ijms-19-02237],[@B25-ijms-19-02237]\], and by another collagenase MMP-13 \[[@B19-ijms-19-02237],[@B26-ijms-19-02237],[@B27-ijms-19-02237]\]. The role of MMP-13 in PAR1-mediated activation in cancer has not been well studied except in context of tumor cell expression \[[@B28-ijms-19-02237],[@B29-ijms-19-02237]\].

MMP-13 was identified as having the capacity to cleave and activate PAR1 on cardiac fibroblasts and cardiomyocytes, which results in pathologic activation of downstream signaling events that contribute to heart failure \[[@B27-ijms-19-02237]\]. Other noncanonical protease agonist of PAR1 such as APC, plasmin, factor Xa, and elastase are important in diverse physiological non-cancer processes \[[@B16-ijms-19-02237],[@B30-ijms-19-02237],[@B31-ijms-19-02237]\].

In particular, collagenase MMP-1 that can degrade type I, II, and III collagens is highly expressed and metastatic in breast cancer \[[@B32-ijms-19-02237]\]. The levels of MMP-1 in tumor samples of node positive patients were significantly higher than in samples of node negative patients and are associated with the 1G/2G polymorphism of the promoter region of MMP-1 in breast cancer patients \[[@B33-ijms-19-02237]\]. Moreover, MMP1-PAR1 activation induced secretion of several angiogenic factors from ovarian carcinoma cells including IL-8, GRO-α, and MCP-1 \[[@B7-ijms-19-02237]\]. In addition, another important role of MMPs is the proteolytic alteration of chemokines \[[@B34-ijms-19-02237]\].

Furthermore, MMP-14 and MMP-2 proteolytically \[[@B35-ijms-19-02237]\] activate TGF-β which is a major tumor promoting factor that leads to increased invasion and metastasis. However, MMPs can generate both angiogenesis promoting and inhibiting signals depending on the cleavage product of the diverse MMPs \[[@B36-ijms-19-02237]\]. MMP-9 and the angiogenesis vascular endothelial growth factor (VEGF) bioavailability switch promote angiogenesis. In contrast, a cleavage of collagen by MMP-3, -7, -9, -13 or -20 can generate biologically active angiostatin, which is a suppressor of angiogenesis.

PAR1 is a member of the family A of GPCRs that belongs to the larger delta subfamily and is most similar to the purinergic, the olfactory, and the glycoprotein receptors. Zheng et al. \[[@B37-ijms-19-02237]\] provided a high 2.2 Å resolution crystal structure of human PAR1 complexed with a PAR1 antagonist, vorapaxar, which was found to bind close to the extracellular surface of PAR1 over a large surface area. The vorapaxar binding pocket in PAR1 resembles rhodopsin and sphingosine-1-phospahate receptor ligand sites. In PAR1, residue D367 forms a strong hydrogen bond that results in displacing the cytoplasmic end of TM7 that is displaced inward towards TM2, which is a position similar to the active conformation of the β2-adrenergic receptor bound to heterotrimeric G protein. Substitution analysis of PAR1 residues and the NMR structure of the extracellular domain provided the bases for the hypothesis that the tethered peptide may first bind, superficially to the extracellular domains as a multistep sequential mechanism before binding more deeply into the core through conformational intermediates. We have generated a lipidated peptide derived from the entire PAR1third intracellular (i3)-loop known as P1pal-19 \[[@B38-ijms-19-02237]\] that can allosterically activate the PAR1 receptor through the TM7 D/NPxxYYY motif through a dimer-like mechanism between the i3 loop and the eight helix \[[@B39-ijms-19-02237]\]. Our early work identified the eighth helix as critical including cysteine palmitoylation and interactions with the adjacent NPXXY motif (TM7) and intracellular loop-1 (i1), which has an important role in the transfer of the signal from PAR1 to the G-protein \[[@B40-ijms-19-02237]\]. Based on the crystal structures of the on and off-states, the D/NPxxYYY containing region undergoes a major structural rearrangement. D367 and Y371 form hydrogen bonds with TM2 and TM1 residues in PAR1, which was suggested previously to be similar to the active β2-adrenergic receptor activation mechanism.

2.2. Diverse Downstream Interactors: Canonical and Non-Canonical Role and Signaling {#sec2dot2-ijms-19-02237}
-----------------------------------------------------------------------------------

PAR1 is activated differentially by distinct canonical (thrombin) and noncanonical (MMP-1) generated tethered ligands within the extracellular N-terminal domain that result in subtle differences in the allosteric mechanisms of activation and transmembrane signaling to a variety of unique downstream integrators ([Figure 2](#ijms-19-02237-f002){ref-type="fig"}). These diverse signaling pathways control the Epithelial-to-Mesenchymal Transition (EMT) and may be related to stem cell biology, tumor progression (migration/invasion/metastasis), angiogenesis, and barrier function ([Table 1](#ijms-19-02237-t001){ref-type="table"}). We will discuss the implications of protease-biased signaling of PAR1 in these critical processes as related to cancer.

### 2.2.1. Role of PAR1 in the Epithelial-to-Mesenchymal Transition (EMT)-Stem Cell {#sec2dot2dot1-ijms-19-02237}

Our work showed that PAR1 ectopic expression leads to cancer stem cell growth associated with an increase in the CD44^high^/CD24^low^ ratio, self-renewal, and anchorage independent growth in breast cancer ([Table 1](#ijms-19-02237-t001){ref-type="table"}) \[[@B41-ijms-19-02237]\]. Multiple examples of up-regulated PAR1 expression in diverse tumors have also been previously reported \[[@B5-ijms-19-02237],[@B52-ijms-19-02237],[@B53-ijms-19-02237]\]. Atopic expression of PAR1 in the MCF7 breast cancer cell line was examined for resultant global changes in gene transcription using the Human Genome U133A 2.0 Array (Affymetrix, Bedford, MA, USA) containing 14,500 human transcripts. Overall, there was a dramatic transcriptional shift in 3397 transcripts with an upregulated expression of mesenchymal markers including vimentin and down-regulation of epithelial markers including E-cadherin as well as the estrogen receptor ([Figure 2](#ijms-19-02237-f002){ref-type="fig"}A). Both canonical and noncanonical activation of PAR1 resulted in direct regulation of vimentin expression. We also found that vimentin expression increased along with the histologic grade of the tumor in breast cancers. In contrast, there was no vimentin expression detected in normal tissue. This remarkable transcriptional shift was highly indicative of a mesenchymal transition. There was an increase in the expression of TGF-β family members that have been well-established as potent inducers of mesenchymal transition in mammary cells that involved acquisition of tumor stem-like properties. E-cadherin was found to be regulated by miR-17 through the NF-κB pathway \[[@B42-ijms-19-02237]\].

The most widely studied EMT regulators include Snail and Twist and either of these transcription factors can induce EMT \[[@B43-ijms-19-02237],[@B54-ijms-19-02237],[@B55-ijms-19-02237],[@B56-ijms-19-02237]\]. Our work found that PAR1 induced a basal-like phenotype in human breast cancer cell lines through the non-histone chromatin-binding protein and a high-mobility-group non-histone chromosomal protein called HMGA2 \[[@B57-ijms-19-02237]\]. HMGA2 has been identified as an essential driver in a variety of cancers \[[@B58-ijms-19-02237],[@B59-ijms-19-02237],[@B60-ijms-19-02237]\]. The TGF-β signaling pathway, in particular TGF-β1, was highly induced in PAR1 expressing cells and was previously identified as an important regulator of HMGA2 \[[@B61-ijms-19-02237]\]. The regulatory role of HMGA2 and PAR1/TGF-β still remains elusive and is currently being investigated.

### 2.2.2. PAR1 and Migration/Invasion/Metastasis/Tumor Progression {#sec2dot2dot2-ijms-19-02237}

Our previous work identified noncanonical MMP-1 as a protease that cleaved and activated PAR1 \[[@B2-ijms-19-02237],[@B18-ijms-19-02237]\]. MMP-1-PAR1 signaling activated survival pathways in breast cancer cells similar to thrombin with distinct kinetics of duration \[[@B4-ijms-19-02237]\]. We also demonstrated that, in some breast cancers, tumor-stromal interactions play a critical role \[[@B2-ijms-19-02237],[@B20-ijms-19-02237]\] and that stromal-derived MMP-1 can drive tumor progression, invasion, and metastasis through the activation of PAR1. Both MMP-1 expression and collagenase activity is upregulated in breast tumors carrying PAR1 as compared to normal mammary pads. The high PAR1 expressing cells showed a dose-response in their ability to proliferate that was directly related to PAR1 surface expression. Akt played a prominent role in cell growth, survival, and proliferation. Persistent activation of Akt was found using both PAR1-expressing breast cancer cells in in vitro and in vivo systems. Persistent MMP1-PAR1-Akt signaling resulted in the metastasis of breast tumors to the lung. Consistent with our findings, work by Bar-Shavit and colleagues identified an association between Akt and PAR1 via the pleckstrin homology (PH) domain in PAR1 \[[@B44-ijms-19-02237]\], which is important in the tumor growth and trophoblast invasion processes that are also lipid (PIP2 and PIP3) driven. Furthermore, biased PAR1 signaling and PAR1-activation with elastase cleaved PAR1 at L~45~\^R~46~, which also resulted in the PH-Akt association and MAPK activation. However, it still remains unclear how the biased PAR1 signaling activated by multiple canonical and noncanonical downstream pathways differentially regulates tumor progression and warrants further investigation.

Constitutive PAR1 signaling may be a consequence due to a loss of tumor suppressor α-arrestin (ARRDC3) and deregulated PAR1 trafficking \[[@B45-ijms-19-02237],[@B62-ijms-19-02237]\]. Another report of the tumor suppressor called ALEX1 in gastric cancer inhibited thrombin-induced metastasis through Rho GTPase and Rac activation \[[@B46-ijms-19-02237]\]. Thrombin mediated PAR1 signaling is regulated through the tumor progression locus 2 (Tpl2) by activating Rac1 and focal adhesion kinase (FAK), which promoted migration through actin cytoskeleton reorganization \[[@B47-ijms-19-02237]\]. Tpl2 ablation down-regulated PAR1 mediated activation of a variety of proinflammatory and proangiogenic factors including *MMPs*, *VEGF*, *Cyr61* and *SDF1α*. In addition to the Tpl2 mediated response, there are reports of thrombin mediated PAR1-G~12/13~ RhoA activation of phospholipase D (PLD) that, in turn, activated Rap1 in 1321N1 and U373MG glioblastoma cells, which is a well-known Ras-GTPase readily activated in platelets \[[@B48-ijms-19-02237]\]. Analogous of the platelet mechanism of activation, Rap1 activated the β1 integrin pathway that led to an increase in FAK and ERK1/2 phosphorylation \[[@B63-ijms-19-02237]\]. A schematic illustration in [Figure 2](#ijms-19-02237-f002){ref-type="fig"}B summarizes G~12,13~-RhoA and G~i,q~-PI3K-mediated activation of Akt, JNK, Tpl2-Rac, and PLD-Rap1-β1 integrin dependent FAK, ERK activation. These PAR1-dependent multiple signaling cascades regulate complex processes of tumor progression that include migration and invasion that ultimately leads to metastasis, which makes PAR1 an attractive and important therapeutic target.

The EGFR transactivation mediates PAR1 and its implications in tumor progression ([Figure 2](#ijms-19-02237-f002){ref-type="fig"}B). Previous reports suggest that proteolytic activation of PAR1 by thrombin-dependent MMP activity resulted in the persistent activation of EGFR and ErbB2/HER2 through extracellular signal-regulated kinase-1 and kinase-2 (ERK1/2) in invasive breast carcinoma \[[@B64-ijms-19-02237],[@B65-ijms-19-02237]\]. The MMP mediated shedding of HB-EGF may be induced by ROS that is dependent on the plasma membrane-associated NADPH oxidase (Nox) family members. In particular, p47^phox^ phosphorylation and NADPH oxidase activation generate a reactive oxygen species (ROS) through O~2~ by using NADPH as an electron donor \[[@B66-ijms-19-02237]\]. For PAR1, thrombin induction resulted in the activation of Rho/ROCK mediated TGF-β activation that, in turn, activated Smad2 complexes \[[@B65-ijms-19-02237]\].

### 2.2.3. PAR1 and Angiogenesis Barrier Function/Dissemination {#sec2dot2dot3-ijms-19-02237}

Angiogenic factors have been well recognized as important contributors toward disseminated tumor growth and metastasis. Multiple studies in breast, ovarian, and lung cancer provide convincing evidence for the role of PAR1 in regulating blood vessel formation and expression of angiogentic factors such as VEGF, IL-8, and GRO-α \[[@B2-ijms-19-02237],[@B5-ijms-19-02237],[@B7-ijms-19-02237]\]. In ovarian cancer, noncanonical MMP1-medited PAR1 activation was critical in regulating chemokine signaling. The role of MMP-1 in highly metastatic human epidermoid carcinoma, HEp3, was shown to be PAR1-dependent and shown to be an important regulator of vascular permeability, tumor cell intravasation, and metastatic dissemination \[[@B50-ijms-19-02237]\] in agreement with our data in vascular integrity \[[@B67-ijms-19-02237],[@B68-ijms-19-02237]\]. Other reports identified thrombin as a regulator of barrier function and a pro-inflammatory and pro-angiogenic mediator through the regulation of Ca^2+^ \[[@B49-ijms-19-02237]\]. Likewise, prothrombin was found to be a major determinant of the metastatic progression of colon cancer cells \[[@B51-ijms-19-02237]\].

3. PAR1 in Cancer Therapeutics {#sec3-ijms-19-02237}
==============================

The pepducin approach is a process to modulate G-protein coupled receptors (GPCRs) is by targeting the intracellular faces of GPCR receptors through pepducin technology \[[@B9-ijms-19-02237],[@B10-ijms-19-02237],[@B39-ijms-19-02237],[@B69-ijms-19-02237],[@B70-ijms-19-02237],[@B71-ijms-19-02237],[@B72-ijms-19-02237],[@B73-ijms-19-02237],[@B74-ijms-19-02237],[@B75-ijms-19-02237],[@B76-ijms-19-02237],[@B77-ijms-19-02237],[@B78-ijms-19-02237]\]. Pepducins are cell-penetrating lipidated peptides designed to target the intracellular (i1--4) loops of the receptor. The pepducin PZ-128, also known as P1pal7 \[[@B9-ijms-19-02237],[@B12-ijms-19-02237],[@B13-ijms-19-02237],[@B79-ijms-19-02237]\] targets PAR1 and has been extensively validated and advanced into the clinical setting with completion of a Phase I clinical trial (*n* = 34 subjects) and a nearly completed Phase II (*n* = 100) multicenter, randomized, placebo-controlled clinical trial to treat severe cardiovascular disease in patients undergoing percutaneous coronary interventions. Below, we will review preclinical data in experimental mouse models of breast, lung, and ovarian cancer that validate PZ-128 and the PAR1 target in these tumors.

3.1. PZ-128 and Breast Cancer Preclincal Studies {#sec3dot1-ijms-19-02237}
------------------------------------------------

Work on PAR1 as an important clinical target with a critical multi-role in thrombosis, inflammation, and vascular biology has been investigated by multiple laboratories since the PAR1 discovery in 1991 as a thrombin receptor \[[@B15-ijms-19-02237]\]. However, under pathophysiological conditions in carcinomas, PAR1 is an oncogenic protein, which is a potent inducer of cancer cell migration, invasion, survival, and metastasis \[[@B3-ijms-19-02237],[@B4-ijms-19-02237],[@B80-ijms-19-02237],[@B81-ijms-19-02237],[@B82-ijms-19-02237],[@B83-ijms-19-02237],[@B84-ijms-19-02237]\]. Our laboratory evaluated PAR1-derived PZ-128 as a potential PAR1 inhibitor to suppress breast cancer progression. The efficacy models are summarized in [Table 2](#ijms-19-02237-t002){ref-type="table"}. PAR1 was atopically expressed in PAR1-null, estrogen-sensitive MCF-7 cells and tested for its ability to promote tumor-growth and invasion in nude mice. PAR1 expression resulted in a 100% rate of tumor formation while PAR1-null MCF-7 cells did not form any palpable tumors ([Table 2](#ijms-19-02237-t002){ref-type="table"}) \[[@B2-ijms-19-02237]\]. These PAR1-driven tumors could be significantly inhibited (62%, *p* \< 0.01) with PZ-128. PAR1-dependent tumor growth was MMP1-mediated because treatment with MMP-1 Inh resulted in 82% inhibition of tumor growth. Tumors were examined for vascularity using von Willebrand Factor. The mean (±2 SEM) blood vessel density was 10.4 ± 2.2 for the untreated group, 2.6 ± 1.0 (*p* = 0.002) for the PZ-128-treated group, and 3.6 ± 1.5 (*p* = 0.006) for the MMP-1 Inh treated group. Therefore, both inhibition of PAR1 and MMP-1 resulted in the inhibition of angiogenesis. Likewise, PAR1 expressing MCF-7 cells could form metastatic lesions in lungs with a 100% penetrance rate similar to the highly metastatic MDA-MB-231 while the PAR1-mutant R310E that lacked signaling abilities had undetectable metastatic lesions in the lung \[[@B41-ijms-19-02237]\]. Most strikingly, there was a similar reduction in the number of metastatic lesions with either treatment as monotherapy, PZ-128, or MMP-1 Inh (75% and 88%, respectively, *p* \< 0.001) \[[@B4-ijms-19-02237]\].

We assessed the efficacy of PZ-128 in a mammary fat pad model with highly invasive, estrogen-independent PAR1-expressing MDA-MB-231 cells. Since Docetaxel (Taxotere) is a chemotherapy drug used to treat breast cancer that has become the standard of care for preoperative neoadjuvant, adjuvant, and metastatic settings \[[@B85-ijms-19-02237]\], it was tested in combination with PZ-128 for efficacy using MDA-MB-231 cells. Dual treatment with Taxotere (10 mg/kg) and PZ-128 (10 mg/kg) was administered early (day 2) and resulted in near complete (98%) (*p* \< 0.05) inhibition of tumor growth. In contrast, monotherapy with either Taxotere or PZ-128 had no effect when compared to the vehicle-treated control \[[@B4-ijms-19-02237]\]. Delayed treatment (day 15) with dual therapy still significantly inhibited (60%, *p* \> 0.01) tumor growth. Upon sectioning, the tumors were stained for apoptosis using the TUNEL process, which identified on average 60% of apoptotic regions within tumors treated with dual therapy.

The Akt survival pathway was identified as an important mechanism of MMP1-PAR1 signaling. Biochemical analysis of MDA-MB-231 derived tumors 200 mm^3^ in size before the start of five-day treatment with PZ-128 (10 mg/kg) or MMP1 Inh (5 mg/kg) together with a single dose of Taxotere (10 mg/kg) were carried out. There was a 54% and 61%, (*p* \< 0.05), respectively, reduction in Akt phosphorylation in tumors with dual treatments. Therefore, pAKT could be potentially used as a direct biomarker for the efficacy of PZ-128 in a clinical setting in the treatment of breast cancer. Taken together, these data provide strong evidence that blockade of PAR1 with PZ-128 and Taxotere could be beneficial in advanced, metastatic breast cancer.

3.2. Efficacy of PZ-128 and Role of MMP-1a in Lung Cancer {#sec3dot2-ijms-19-02237}
---------------------------------------------------------

PAR1 is a poor prognostic marker in lung cancer that correlates with reduced survival in non-small-cell lung cancer (NSCLC) \[[@B86-ijms-19-02237]\]. In 2007, bevacizumab (Avastin) in combination with carboplatin and paclitaxel was approved as the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous NSCLC \[[@B87-ijms-19-02237]\]. We carried a comparative efficacy study of PZ-128 versus Avastin in a well-established A549 xenograft model of lung adenocarcinoma injected subcutaneously in the flank of the mouse. PZ-128 and Avastin significantly inhibited tumor growth (*p* \< 0.01) with 75% and 67% inhibition, respectively ([Table 2](#ijms-19-02237-t002){ref-type="table"}, \[[@B5-ijms-19-02237]\]). We also showed that PAR1 can regulate VEGF production through the ERK1/2-dependent signaling pathway. Therefore, patients with metastatic NSCLC may benefit from the ERK1/2 blockade. Further studies are needed in order to determine if PZ-128 could induce a therapeutic response.

The role of MMP-1 in NSCLC is not well understood. In order to address the role of mouse homolog MMP-1a, knockout mice were generated (*MMP1a*-KO) \[[@B23-ijms-19-02237]\]. Lewis lung carcinoma (LLC1) is a highly tumorigenic cell line that expresses high levels of PAR1. Mouse LLC1 cells were implanted subcutaneously into the abdominal fat pad of *MMP1a*-KO and wild type (WT) C57CL/6 mice. The progression of tumor growth was followed over 26 days. The loss of stromal MMP1a resulted in a 50% reduction of tumor growth when compared to WT-MMP1a mice (*p* \< 0.001). There was a significant decrease (30%) (*p* \< 0.01) in angiogenesis in the *Mmp1a*-KO mice when compared to wild-type mice.

In order to verify that MMP-1a tumor growth was PAR1-mediated in LLC1 cells, PAR1 was stably silent due to using a short hairpin-RNA (shPAR1) or control (shLuci). Consistent with our hypothesis, LLC1 (shPAR1) lagged in growth and formed smaller tumors (31% inhibition, *p* \< 0.001) when compared to LLC1 (shLuci). Together these data provide support for the role of a mouse homolog of human MMP-1, namely MMP-1a in activation of PAR1.

3.3. PZ-128 as a Therapeutic Target in Ovarian Cancer {#sec3dot3-ijms-19-02237}
-----------------------------------------------------

Ovarian cancer is still one of the deadliest gynecologic malignancy because of an early metastatic spread into the abdominal cavity. Despite some advances, a taxane such as Docetaxel still remains the standard-of-care in combination with a platinum compounds (cisplatin or carboplatin). A murine metastatic model of intraperitoneal (i.p.) ovarian cancer was conducted by injecting extremely aggressive and metastatic OVCAR-4 cells into an intraperitoneal cavity. The treatment regimen was PZ-128 (3.2 mg/kg i.p. every other day) or MMP-1 Inh (5 mg/kg) in combination with Docetaxol (10 mg/kg i.p. once weekly). Metastatic progression was determined using a histological staging system that consisted of examining metastatic progression through omentum and invading through the diaphragm with metastasis to the lung and heart. All untreated (vehicle treated) mice had full-blown metastasis through the diaphragm and into the lungs and mediastinum ([Table 2](#ijms-19-02237-t002){ref-type="table"}) \[[@B6-ijms-19-02237]\]. In contrast, dual therapy with PZ-128 prevented invasion across the diaphragm into a thoracic cavity (*p* = 0.01) relative to docetaxol alone. Similar results were observed with MMP-1 Inh (*p* = 0.003). These data strongly support an MMP1-PAR1 signaling pathway as an important target for preventing the metastatic spread in ovarian cancer. There was a significant reduction (73% to 92%) in blood vessel formation with dual PZ-128 and dual MMP-1 Inhibitor therapy as compared to docetaxol alone. The mean (±2 SEM) blood vessel density was 13.7 ± 1.5 for the vehicle treated group, 8.1 ± 2.2 for the docetaxel group, 2.2 ± 0.4 (*p* \< 0.005) for the PZ-128-treated group, 2.2 ± 0.4 (*p* \< 0.005) for the dual PZ-128 + docetaxel group, and 3.0 ± 0.5 (*p* \< 0.005) for the MMP-1 Inh + docetaxel treated group. Therefore, monotherapy with PZ-128 and MMP-1 Inh significantly inhibited blood vessel formation.

Ovarian peritoneal carcinomas produce large volumes of ascitic fluid. Using OVCAR-4 and SKOV-3 peritoneal carcinoma models, there was significant inhibition (60%, *p* = 0.0017) of ascitic fluid accumulation using PZ-128 as monotherapy (10 mg/kg every second day) when compared to vehicle control in an OVCAR-4 peritoneal carcinoma model. Similar results were seen with SKOV-3 cells. This effect on ascites accumulation may be a direct effect of an MMP1-PAR1 dependent endothelial barrier function. Taken together, PZ-128 is an excellent therapeutic for ovarian cancer treatment.

4. Pepducin Technology and Anti-Cancer Therapy: Future Prospective {#sec4-ijms-19-02237}
==================================================================

PAR1 is a well-known target on human platelets that may benefit high-risk patients with a history of myocardial infraction (MI) or peripheral arterial disease (PAD) and reduce thrombotic events. Vorapaxar, atopaxar, and PZ-128 are the three PAR-1 antiplatelet agents that have undergone clinical development to various stages ([Table 3](#ijms-19-02237-t003){ref-type="table"}). Vorapaxar is the first PAR-1 antagonist that was approved by the US Food and Drug Administration (in US and Europe) in May 2014 to reduce the risk of MI, stroke, and cardiovascular death and for the revascularization in patients with a previous MI or PAD (US). Vorapaxar is counter-indicated in patients with a history of prior stroke or transient ischemic attack (TIA). Since antiplatelet therapy is given on top of two other drugs (aspirin and P2Y12 inhibitors), there was a risk of increased bleeding with both vorapaxar and atopaxar. The use of the approved drug varapaxar as an anti-platelet agent is not clear due to safety concerns. However, this is less likely with PZ-128 because it is only given as a single IV dose to coronary artery disease (CAD) and acute coronary syndrome (ACS) patients during PCI. Currently, PZ-128 is well positioned as a promising antiplatelet agent that showed rapid platelet PAR1 inhibition appearing at 15 min which is faster than the P2Y12 oral drug clopidogrel (Plavix) used as the standard of care for patients undergoing percutaneous coronary intervention (PCI). PZ-128 has a plasma half-life of about 2 h and a pharmacodynamic half-life of about 24 h with 65--100% inhibition of PAR1 activity by 30 min \[[@B13-ijms-19-02237]\]. There were no effects on bleeding, coagulation, clinical chemistry, or electrocardiography (ECG) parameters. The PZ-128 inhibitory effect was fully reversible with saturating concentrations of the PAR1 agonist.

The question remains whether PZ-128 or other currently developed PAR1 drugs could be used for the treatment of metastatic breast, lung, or ovarian cancers. PAR1-biased signaling is orchestrated by a diverse set of unique proteases canonical (thrombin) and noncanonical (MMP-1, MMP-13, elastase, APC) that cleave PAR1 and may stabilize diverse allosteric conformations that are perfectly tuned to activate diverse down-stream signaling ([Figure 2](#ijms-19-02237-f002){ref-type="fig"}). Therefore, the pepducin approach could provide an advantage because it could inhibit diverse allosteric conformations at the receptor-G-protein interface. Direct pharmacologic comparative studies in relevant cancer cell lines between vorapaxar, atopaxar, PZ-128 and other PAR1-derived pepducins using a set of proteases agonists such as thrombin, MMP-1, MMP-13 and elastase could address this question. Pepducin technology can readily target other parts of the receptor-G-protein interface to lead to design of a biased antagonists with favorable pharmacologies.

In summary, we provide evidence for the PAR1 inhibitor PZ-128 as an anti-metastatic and anti-angiogenic inhibitor in breast, lung, and ovarian cancer murine models and other relevant systems. We show synergy between deoxycycline (the standard-of-care) and PZ-128 as a therapeutic approach in breast and ovarian cancers. Furthermore, our results provide a mechanistic rationale for the use of a PAR1 inhibitor for breast cancer therapy and the employment of Akt and HMGA2 as potential biomarkers for efficacy.
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structural protein

PH

plekstrin homology

Etk

tyrosine kinase

ARRDC3

Arrestin domain containing 3β-arrestin protein

JNK

Jun-N-terminal kinase

ALEX1

a tumor-suppressor member of the armadillo family

Tpl2

tumor progression locus 2 kinase

Rac1

Rho GTPase

PLD

phospholipase D

RhoA,Rap1A

Ras related GTPases

ERK

the extracellular signal-regulated kinase

VEGF

vascular endothelial growth factor

CXCR1/2

C-X-C chemokine receptors 1 and 2

ROS

reactive oxygen species

MMP-1

matrix metalloproteinase 1

PAR1

protease activated receptor 1

Human MCF7-PAR1 (clone N55)

stable high PAR1 expressing MCF7 clone 55 (note MCF-7 cells don not express PAR1)

PAR1-null

lack of PAR1 expression

Human MCF7-PAR1 (R310E)

stable cell line expression PAR1 with an R310E mutation that results in high expression of a PAR1 non-signaling receptor

NCR nu/nu mice

immuno-deficient mouse model

MMP-1 Inh

FN439 matrix metalloprotease 1 inhibitor

vWF

von Willebrand Factor

Human MDA-MB-231

PAR1 expressing breast cancer cell line

PZ-128

also known as P1pal-7 is the PAR1 antagonist pepducin

metastatic incidence

appearance of macroscopic tumor nodules at the surface of lung or using histologic analysis of lung sections

tumor incidence

number of tumors formed after subcutaneous implantation into mammary fat pads

TUNEL

terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling

A549

human PAR1 expressing lung adenocarcinoma

LLC1

mouse Lewis lung carcinoma

LLC1-shPAR1

a short hairpin-RNA that silenced PAR1 expression

LLC1-shControl

control (shLuciferase)

MMP1a-KO

MMP1 knockout mouse

OVCAR-4 and SKOV-3

Human ovarian cell lines

Ascites formation

production of large volume of fluid in the peritoneal cavity

Intraperitoneal cavity

space between the abdominal wall and the surrounding interanal organs

Peritoneal carcinomatosis

mice were injected into the peritoneal cavity with ovarian cancer cells

FAK

ERK1/2

focal adhesion kinase

extracellular signal-regulated kinase 1 and 2

![PAR1 biased signaling is orchestrated by a diverse set of unique proteases, both noncanonical (MMP-1) and canonical (thrombin). PAR1 activation by MMP-1 and thrombin results in two different cleavage sites with the MMP-1 generated activating peptide (AP) PR-SFLLRN-NH~2~ and the thrombin generated SFLLRN-NH~2~. N-terminal cleavage sites are listed for MMP-13, Elastase, and APC. Tethered AP sequences are shown for Elastase and APC.](ijms-19-02237-g001){#ijms-19-02237-f001}

![(**A**). Schematic diagram of PAR1 and HMGA2, Twist/Snail mediated transcriptional regulation of mesenchymal markers, and down-regulation of epithelial markers. Both HMGA2 and Twist further regulate expression of PAR1. TGF-β has a prominent role in the regulation of these processes and stem cell markers. PAR1-biased signaling is orchestrated by a diverse set of unique proteases canonical (thrombin) and noncanonical (MMP-1, MMP-13, elastase, APC) that cleave the PAR1 extracellular loop 1 (e1) at indicated amino acid residues. (**B**) Multiple signaling pathways control PAR1-mediated tumor progression (migration, invasion, and metastasis) that are mediated through PAR1 coupled G-proteins including G~12,13~ and G~i,q~. PAR1 is constitutively turned on as a result of defective PAR1 trafficking. Parallel PAR1 signaling pathways through G~12,13~-RhoA link outside extracellular matrix signals with β1 integrin, TGF-β, and EGFR transactivation that regulate proliferative and migratory responses (ERK1/2, FAK, Smad2) while G~i,q~-PI3K harness Akt-survival pathways and Rac result in the invasion and, ultimately, in metastasis.](ijms-19-02237-g002){#ijms-19-02237-f002}
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###### 

Summary of PAR1-medicated signaling pathways that regulate Epithelial-to-Mesenchymal Transition (EMT), tumor progression, and angiogenesis/barrier function in solid tumors.

  PAR1                          Canonical/Non-Canonical   Signaling Pathways                         Function                                         Ref
  ----------------------------- ------------------------- ------------------------------------------ ------------------------------------------------ --------------------------
  Breast Cancer                 Canonical/noncanonical    HMGA2/EMT                                  EMT/metastasis                                   \[[@B41-ijms-19-02237]\]
  Breast Cancer                                           NF-κB/miR-17/E-cadherin                    EMT                                              \[[@B42-ijms-19-02237]\]
  Cancer Stem Cell                                        Twist/Hippo pathway/TAZ                    EMT                                              \[[@B43-ijms-19-02237]\]
  Breast Cancer                 Noncanonical              Akt/E-cadherin/vimentin                    Metastasis                                       \[[@B4-ijms-19-02237]\]
  Breast Cancer                 Canonical                 plekstrin homology (PH)-Akt/Etk/Bmx/Vav3   Cell invasion                                    \[[@B44-ijms-19-02237]\]
  Basal-like breast carcinoma                             α-arrestin (ARRDC3)/JNK                    Cell invasion                                    \[[@B45-ijms-19-02237]\]
  Gastric cancer                                          ALEX1/Rho GTPase                           Tumor progression                                \[[@B46-ijms-19-02237]\]
  Breast Cancer                 Canonical                 Tpl2/Rac1/FAK                              Migration                                        \[[@B47-ijms-19-02237]\]
  U373MG glioblastoma           Canonical                 PLD/RhoA/Rap1A/β1 integrin/FAK/ERK         Proliferation, tumor growth                      \[[@B48-ijms-19-02237]\]
  Breast Cancer                 Noncanonical                                                                                                          
  Lung Cancer                                             VEGF                                       Angiogenesis                                     \[[@B5-ijms-19-02237]\]
  Ovarian cancer                Noncanonical              CXCR1/2                                    Angiogenesis                                     \[[@B7-ijms-19-02237]\]
  Endothelial cells             Canonical                 Ca^2+/^Na^+^/Ca^2+^ exchange/ROS/ERK1,2    Angiogenesis/barrier function                    \[[@B49-ijms-19-02237]\]
  HEp3 epidermoid carcinoma     Noncanonical              Tumor MMP-1                                Dissemination/vascular permeability metastatic   \[[@B50-ijms-19-02237]\]
  Colon Cancer                  Canonical                 fibrinogen, stromal PAR1                   Disseminated growth                              \[[@B51-ijms-19-02237]\]
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###### 

Summary of preclinical studies carried out with PZ-128 and the MMP-1 Inhibitor in breast, lung, and ovarian cancer.

  Cell                                          Tumor Model                                                                          Type of Assay                              Outcome                                                                                                                                     Ref
  --------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------
  *Breast Cancer*                                                                                                                                                                                                                                                                                                           
  MCF7-PAR1 (clone N55)                         Mammary fat pad NCR nu/nu mice                                                       xenograft model (tumor size)               \>PAR1-tumor incidence 100% PAR1-null 0% after 6 weeks                                                                                      \[[@B2-ijms-19-02237]\]
  xenograft model (tumor size)                  \>PZ-128 (10 mg/kg) inhibits 62% MMP-1 Inh (5 mg/kg) inhibits 82% of tumor growth                                                                                                                                                                                           
  histology vWF                                 \>65% to 75% inhibition in angiogenesis                                              \[[@B2-ijms-19-02237]\]                                                                                                                                                                
  MDA-MB-231                                    Mammary fat pad NCR nu/nu mice                                                       xenograft model (tumor size)               \>dual treatment with PZ-128/Taxotere (Docetaxel) treatment day 2 98% inhibition                                                            \[[@B4-ijms-19-02237]\]
  xenograft model (tumor size) TUNEL staining   \>delayed dual treatment day 15 60% inhibition of tumor growth, 60% apoptotic area   \[[@B4-ijms-19-02237]\]                                                                                                                                                                
  MDA-MB-231                                    Mammary fat pad NCR nu/nu mice                                                       Western blot                               \>pAkt as biomarker inhibited 54% by PZ-128 after 5-day treatment MMP-1 Inh 5-day treatment 61% Inhibition                                  \[[@B4-ijms-19-02237]\]
  MDA-MB-231/GFP                                Metastasis to lung NCR nu/nu mice Tail vein                                          lung histology                             \>reduction in metastatic incidence by PZ-128 75% MMP-1 Inh 88% inhibition                                                                  \[[@B4-ijms-19-02237]\]
  MCF7-PAR1 (clone N55)                         Metastasis to lung NCR nu/nu mice Tail vein                                          lung histology                             \>PAR1-tumor incidence 100%                                                                                                                 \[[@B41-ijms-19-02237]\]
  MDA-MB-231                                    Metastasis to lung NCR nu/nu mice Tail vein                                          lung histology                             MDA-MB-231 tumor incidence 100%                                                                                                             \[[@B41-ijms-19-02237]\]
  MCF7-PAR1 (R310E)                             Metastasis to lung NCR nu/nu mice Tail vein                                          lung histology                             R310E tumor incidence 0%                                                                                                                    \[[@B41-ijms-19-02237]\]
  *Lung Cancer*                                                                                                                                                                                                                                                                                                             
  A549 NCR nu/nu mice                           subcutaneous                                                                         xenograft model tumor size                 \>75% inhibition of tumor growth PZ-128 monotherapy (10 mg/kg) Compared to Avastin (5 mg/kg) 67% inhibition of tumor growth                 \[[@B5-ijms-19-02237]\]
  LLC1 *MMP1a*-KO mice C57Bl (WT) mice          subcutaneous                                                                         xenograft model tumor size histology vWF   \>LLC1 tumor growth in *MMP1a*-KO mice vs WT have 50% inhibition 30% inhibition in angiogenesis                                             \[[@B21-ijms-19-02237],[@B22-ijms-19-02237],[@B23-ijms-19-02237]\]
  LLC1-shPAR1 LLC1-shControl                    subcutaneous                                                                         xenograft model tumor size                 \>31% inhibition in tumor growth with shPAR1                                                                                                \[[@B23-ijms-19-02237]\]
  *Ovarian Cancer*                                                                                                                                                                                                                                                                                                          
  OVCAR-4                                       Intraperitoneal cavity                                                               Endothelial barrier                        \>PZ-128 (10 mg/kg i.p. every other day) reduced ascites formation by 60%                                                                   \[[@B6-ijms-19-02237]\]
  SKOV-3                                        Intraperitoneal cavity                                                               Endothelial barrier                        reduced ascites formation by 60%                                                                                                            \[[@B6-ijms-19-02237]\]
  OVCAR-4                                       Peritoneal carcinomatosis                                                            Histology                                  \>84% to 96% inhibition of angiogenesis monotherapy with MMP1 Inh and PZ-128                                                                \[[@B6-ijms-19-02237]\]
  OVCAR-4                                       Peritoneal carcinomatosis                                                            Histology                                  \>dual treatment with PZ-128 or MMP-1 Inh/Taxotere (Docetaxel) inhibition of metastatic progression through diaphragm and thoracic cavity   \[[@B6-ijms-19-02237]\]
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###### 

Vorapaxar, atopaxar, and PZ-128 are the three PAR-1 antiplatelet agents that have undergone clinical development.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PAR1 Drug                             Clinical Trials                                                                                                                                                                                                     Indication                                                             Results                                                                                           Adverse Events
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  **Vorapaxar (Zontivity)SCH 530348**   Phase 3 \[[@B88-ijms-19-02237],[@B89-ijms-19-02237],[@B90-ijms-19-02237]\] TRA 2P-TIMI50 \[[@B89-ijms-19-02237]\] (*n* = 26,499) TRACER (*n* = 12,944)                                                              Coronary Artery Disease (patients with high risk of ischemic events)   Significantly reduced the occurrence of the primary endpoint, CV death, MI, or stroke             Increased risk of intracranial hemorrhage (ICH)

  **Atopaxar**\                         Phase 2 LANCELOT-ACS \[[@B91-ijms-19-02237]\] *n* = 603 J-LANCELOT-ACS \[[@B92-ijms-19-02237]\] (*n* = 241) LANCELOT-CAD \[[@B93-ijms-19-02237]\] (*n* = 720) J-LANCELOT-CAD \[[@B94-ijms-19-02237]\] (*n* = 263)   Coronary Artery Disease                                                Increased bleeding (TIMI classification)                                                          Transient elevation in liver transaminases and dose-dependent QTc prolongation without apparent complications
  **E5555**                                                                                                                                                                                                                                                                                                                                                                                                                          

  **PZ-128**                            Phase 1 \[[@B13-ijms-19-02237]\] *n* = 32; Phase 2 (NCT02561000) TRIP-PCI *n* = 100                                                                                                                                 Coronary Artery Disease                                                Anti-platelet effect no effects on bleeding, coagulation, clinical chemistry, or ECG parameters   Drug is well tolerated during IV infusion at therapeutic doses of 0.5 mg/kg
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
